|
시장보고서
상품코드
1272774
세계의 흉선암 시장(2023-2030년)Global Thymus Cancer Market - 2023-2030 |
||||||
시장 개요
세계 흉선암 시장은 2022년 4억 6,140만 달러에 달할 것으로 예상되며, 2030년에는 7억 250만 달러에 달할 것으로 예측됩니다. 흉선암 시장은 예측 기간(2023-2030년) 동안 5.5%의 CAGR을 보일 것으로 예상됩니다. 주요 기업들은 흉선암 시장에서 강력한 경쟁자로 부상하기 위해 파트너십, 합병, 인수, 제품 승인, 지역 확장 등의 전략을 채택하고 있습니다.
예를 들어, 2023년 1월 17일 머크의 항 PD-1 치료제 키트루다(KEYTRUDA)가 수술적 절제 및 백금 기반 화학요법(NSCLC) 후 비소세포폐암(NSCLC) 성인 환자의 보조요법으로 단독요법으로서 미국 식품의약국(FDA)의 승인을 받았습니다.
흉선암은 흉선에 악성(암) 세포가 생기는 질환입니다. 흉선종, 흉선암, 흉선 신경내분비종양(TNET)은 흉선상피종양(TET)이라고도 불리며, 흉선의 외부 표면을 덮고 있는 세포에 생기는 희귀암의 일종입니다. 시장 개발의 발전, 흉선암 사례 증가, 연구 활동 증가는 예측 기간 동안 세계 흉선암 시장의 성장을 가속할 것으로 예상되는 요인 중 일부입니다.
시장 역학
흉선암 환자 증가는 흉선암 시장 성장을 가속할 것이다
흉선암의 유병률 증가는 시장 성장을 가속할 것으로 예상됩니다. 예를 들어, Cancer Research UK에 따르면 흉선암은 드물다. 영국에서는 매년 약 345명이 흉선암 진단을 받습니다. 여기에는 흉선종과 흉선암이 포함됩니다.
그러나 정확한 숫자는 알려져 있지 않으며, 컴퓨터 단층 촬영으로 감지할 수 있는 추정치보다 더 많을 수 있습니다. 흉선종과 흉선암은 일반적으로 40-60세에서 발생하지만, 거의 모든 연령대에서 발생할 수 있습니다. 따라서 노인 인구 증가는 흉선암의 유병률에 기여하는 것으로 보입니다.
연구 활동 활성화로 시장 성장 기회 창출
흉선암에 대한 새로운 치료법을 개발하기 위한 몇 가지 접근법이 있으며, 흉선암 시장은 향후 몇 년 동안 유리한 성장 기회를 얻을 수 있습니다. 예를 들어, 연구자들은 면역 체계의 힘을 이용하여 암세포를 표적으로 삼아 파괴하는 면역 요법의 사용을 모색하고 있습니다. 또한 흉선암의 발생과 진행에 관여하는 특정 분자 경로에 초점을 맞춘 표적 치료와 같은 접근법도 고려되고 있습니다.
코로나19의 영향 분석
코로나19 분석에는 Pre-COVID 시나리오, COVID 시나리오, Post-COVID 시나리오가 포함되어 있으며, 가격 역학(팬데믹 기간 및 팬데믹 이후 가격 변동과 COVID 이전 시나리오와의 비교), 수급 스펙트럼(거래 제한, 봉쇄 및 이후 공급과 수요의 변화), 정부의 이니셔티브(정부 기관 시장, 부문 및 산업 활성화 노력), 제조업체의 전략적 노력(제조업체의 COVID 문제 완화 노력)에 대한 설명도 포함되어 있습니다.
러시아-우크라이나 분쟁 분석
러시아-우크라이나 분쟁이 세계 흉선암 시장에 미치는 영향은 이 지역에 주요 시장 관계자가 없고 이 질환의 유병률이 전반적으로 낮기 때문에 거의 무시할 수 있는 수준일 것으로 추정됩니다. 그러나 이 전쟁은 이 지역에서 진행되는 연구 활동을 둔화시켜 세계 흉선암 시장에 가장 작은 영향을 미칠 것으로 예상됩니다.
세계적 불황의 영향 분석
헬스케어 산업이 불황과 전혀 무관한 것은 아닙니다. 하지만 이 산업은 그 특성상 다른 분야보다 더 잘 대처하고 있습니다. 불황은 연구 투자 감소로 이어져 지난 몇 년 동안 시장 성장에 부정적인 영향을 미쳤습니다.
인공지능의 영향력 분석
다양한 암에 대한 AI의 적용은 불균형적이며, 종격동 종양에 충분한 관심을 기울이지 않아 큰 격차와 향후 발전 가능성을 보여주고 있습니다. 예를 들어, 산터우 중앙병원 방사선과 연구진은 머신러닝 기반 CT 영상이 조사에서 다양한 조직학적 분류와 침윤 수준 예측에 유의미한 값을 보였다고 결론지었습니다. 이처럼 인공지능은 향후 몇 년 동안 세계 흉선암 시장에 긍정적인 영향을 미칠 것으로 추정됩니다.
이 보고서에 대해 자세히 알아보기 - 샘플 요청하기
목차
제1장 조사 방법과 범위
- 조사 방법
- 조사 목적 및 조사 범위
제2장 정의와 개요
제3장 주요 요약
- 암 유형별 개요
- 치료법별
- 최종사용자별
- 지역별 개요
제4장 시장 역학
- 영향요인
- 성장 촉진요인
- 신흥 국가 시장 개척 활성화
- 연구 활동 활성화
- 성장 억제요인
- 질환에 대한 낮은 이해도
- 기회
- 자금조달과 투자 증가
- 영향 분석
- 성장 촉진요인
제5장 산업 분석
- Porter의 Five Forces 분석
- 공급망 분석
- 미충족 요구
- 법규제 분석
제6장 COVID-19 분석
- COVID-19 분석
- COVID-19 이전의 시나리오
- 현재의 시나리오
- COVID-19 이후 또는 향후의 시나리오
- COVID-19 기간의 가격 및 역학
- 수급 스펙트럼
- 팬데믹 기간의 시장에 관련된 정부 이니셔티브
- 제조업체의 전략적 이니셔티브
- 끝에
제7장 러시아·우크라이나 전쟁 분석
제8장 세계 동시 불황 분석
제9장 인공지능(AI)의 영향 분석
제10장 암 유형별
- 흉선종
- A형
- AB형
- B1형
- B2형
- B3형
- 흉선암
- 흉선 신경내분비종양(TNET)
- 기타
제11장 치료법별
- 수술요법
- 화학요법
- Doxorubicin (Adriamycin)
- Cisplatin (Platinol)
- Carboplatin (Paraplatin)
- 기타
- 방사선 요법
- 기타
제12장 최종사용자별
- 병원
- 암 치료 및 연구센터
- 외래수술센터(ASC)
- 학술기관 및 연구기관
제13장 지역별
- 북미
- 미국
- 캐나다
- 멕시코
- 유럽
- 독일
- 영국
- 프랑스
- 이탈리아
- 스페인
- 기타 유럽
- 남미
- 브라질
- 아르헨티나
- 기타 남미
- 아시아태평양
- 중국
- 인도
- 일본
- 호주
- 기타 아시아태평양
- 중동 및 아프리카
제14장 경쟁 구도
- 경쟁 시나리오
- 시장 점유율 분석
- 인수합병(M&A) 분석
제15장 기업 개요
- Merck & Co., Inc.
- 기업 개요
- 제품 포트폴리오와 설명
- 재무 개요
- 주요 발전 상황
- Viatris Inc.
- F. Hoffmann-La Roche Ltd
- Elekta AB
- Asensus Surgical US, Inc.
- Pfizer Inc.
- Getwell Pharmaceuticals
- Bristol-Myers Squibb Company
- Intuitive Surgical
- Varian Medical Systems, Inc.(Siemens Healthineers AG)
제16장 부록
LSH 23.05.22Market Overview
The global thymus cancer market reached US$ 461.4 million in 2022 and is projected to witness to reach up to US$ 702.5 million by 2030. The thymus cancer market is expected to exhibit a CAGR of 5.5% during the forecast period (2023-2030). The key players are adopting strategies such as partnerships, mergers, acquisitions, product approvals, and regional expansion to stand out as strong competitors in the thymus cancer market.
For instance, on January 17, 2023, for adult patients with stage IB (T2a 4 cm), stage II, or stage IIIA non-small cell lung cancer, Merck's anti-PD-1 medication, KEYTRUDA, was approved by the U.S. Food and Drug Administration (FDA) as a single agent for adjuvant treatment after surgical resection and platinum-based chemotherapy (NSCLC).
Thymus cancer is a disease in which malignant (cancer) cells form in the thymus. Thymoma, Thymic Carcinoma, and Thymic Neuroendocrine Tumor (TNET) also called thymic epithelial tumors (TETs), are types of rare cancers that can form in the cells covering the thymus's outside surface. The increasing market developments, growing cases of thymus cancer, and increasing research activities are some of the factors that are expected to drive the global thymus cancer market growth over the forecast period.
Market Dynamics
The increasing cases of thymus cancer are driving the thymus cancer market growth
The increasing prevalence of thymus cancer is expected to boost the market growth. For instance, according to Cancer Research UK, thymus gland cancer is rare. In the U.K., around 345 people are diagnosed with thymus cancer each year. This includes thymoma and thymic carcinoma.
However, the exact number is not known and may be higher than the estimated number that can be detected using computed tomography scans. Thymoma and thymic carcinoma usually occurs in people between the ages of 40 and 60 but can occur at almost any age. Thus, the rising older population is likely to contribute to thymus cancer prevalence.
The growing research activities provide the market with growth opportunities
There are several approaches that could be pursued to develop new treatments for thymus cancer presenting the thymus cancer market with lucrative growth opportunities in the forthcoming years. For example, researchers are exploring the use of immunotherapies, which harness the power of the immune system to target and destroy cancer cells. Other potential approaches include targeted therapies that focus on specific molecular pathways involved in the development and progression of thymus cancer.
COVID-19 Impact Analysis
The COVID-19 analysis includes Pre-COVID Scenario, COVID Scenario, and Post-COVID Scenario along with pricing dynamics (including pricing change during and post-pandemic comparing it to pre-COVID scenarios), demand-supply spectrum (shift in demand and supply owing to trading restrictions, lockdown, and subsequent issues), government initiatives (initiatives to revive market, sector or industry by government bodies) and manufacturers strategic initiatives (what manufacturers did to mitigate the COVID issues will be covered here).
Russia-Ukraine Conflict Analysis
The Russia-Ukraine war is estimated to have nearly negligible impact on the global thymus cancer market, owing to the absence of key market players in this region and the overall low prevalence of the condition. Still, the war has slowed the research activities carried out in this region, which is expected to have the slightest impact on the global thymus cancer market.
Global Recession Impact Analysis
The healthcare industry is not completely immune to recession, as healthcare institutions thought firings and employing freezes during past financial downturns. That stated, the industry does cope finer than other sectors because of its essential nature. The recession has led to a decrease in research investments which has negatively impacted the market growth in the past few years.
Artificial Intelligence Impact Analysis
The application of AI in different cancers is disproportionate, and enough attention has not been paid to mediastinal tumors, showing a huge gap and potential for future development. For instance, the researchers from the Department of Radiology, Shantou Central Hospital concluded that the machine learning-based CT image had significant values in the prediction of different histological classifications and even invasion levels from their investigation. Thus, artificial intelligence is estimated to positively impact the global thymus cancer market in the upcoming years.
For more details on this report - Request for Sample
Segment Analysis
The global thymus cancer market is segmented based on cancer type, treatment, end users, and region.
The surgical treatment segment is estimated to hold 39.3% of the total market by 2030
Surgical removal of the tumor is the primary form of treatment for thymus cancer. An incision is made in the center of the chest and the sternum (chest bone) is split, allowing the surgeon full access to the thymus gland. Depending on the extent of cancer, the tumor is removed and the entire thymus gland is removed (a procedure called a thymectomy), and/or parts of nearby organs where the tumor has spread. Moreover, the rising clinical research activities are boosting the surgery treatment segment growth in the forecast period.
For instance, in 2022, according to ClinicalTrials.com., Shanghai Zhongshan Hospital completed an interventional study comparing the safety and perioperative outcomes of the subxiphoid approach versus lateral intercostal approach thoracoscopic thymectomy for Masaoka-Koga I-II Thymoma.
Geographical Analysis
Europe is estimated to hold the second-largest share of the global thymus cancer market during the forecast period
The increasing initiatives and funding in the fight against thymus cancer in this region are boosting the European thymus cancer market growth and are estimated to hold around 26.2% of the global thymus cancer market by 2030. For instance, ThymicUK, a registered charity established by patients with thymic cancers, their carers, and families and friends, raised slightly more than £10,000 from fundraisers and grants to support those impacted by rare thymic cancers.
Competitive Landscape
The major global players in the market include Merck & Co., Inc., Viatris Inc., F. Hoffmann-La Roche Ltd, Elekta AB, Asensus Surgical US, Inc., Pfizer Inc., Getwell Pharmaceuticals, Bristol-Myers Squibb Company, Intuitive Surgical and Varian Medical Systems, Inc. (Siemens Healthineers AG) among others.
Why Purchase the Report?
- To visualize the global thymus cancer market segmentation based on product, application, and region, as well as understand key commercial assets and players.
- Identify commercial opportunities by analyzing trends and co-development.
- Excel data sheet with numerous data points of thymus cancer market-level with all segments.
- PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
- Product mapping available as Excel consisting of key products of all the major players.
The global thymus cancer market report would provide approximately 53 tables, 54 figures, and 195 Pages.
Target Audience 2023
- Manufacturers/ Buyers
- Industry Investors/Investment Bankers
- Research Professionals
- Emerging Companies
Table of Contents
1. Methodology and Scope
- 1.1. Research Methodology
- 1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
- 3.1. Snippet by Cancer Type
- 3.2. Snippet by Treatment
- 3.3. Snippet by End User
- 3.4. Snippet by Region
4. Dynamics
- 4.1. Impacting Factors
- 4.1.1. Drivers
- 4.1.1.1. Increased Market Developments
- 4.1.1.2. Increasing Research Activities
- 4.1.2. Restraints
- 4.1.2.1. Limited Disease Understanding
- 4.1.3. Opportunity
- 4.1.3.1. Increasing Fundings and Investments
- 4.1.4. Impact Analysis
- 4.1.1. Drivers
5. Industry Analysis
- 5.1. Porter's Five Forces Analysis
- 5.2. Supply Chain Analysis
- 5.3. Unmet Needs
- 5.4. Regulatory Analysis
6. COVID-19 Analysis
- 6.1. Analysis of COVID-19
- 6.1.1. Before COVID-19 Scenario
- 6.1.2. Present COVID-19 Scenario
- 6.1.3. Post COVID-19 or Future Scenario
- 6.2. Pricing Dynamics Amid COVID-19
- 6.3. Demand-Supply Spectrum
- 6.4. Government Initiatives Related to the Market During the Pandemic
- 6.5. Manufacturers' Strategic Initiatives
- 6.6. Conclusion
7. Russia-Ukraine War Analysis
8. Global Recession Analysis
9. Artificial Intelligence Impact Analysis
10. By Cancer Type
- 10.1. Introduction
- 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
- 10.1.2. Market Attractiveness Index, By Cancer Type
- 10.2. Thymoma
- 10.2.1. Introduction
- 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 10.2.3. Type A
- 10.2.4. Type AB
- 10.2.5. Type B1
- 10.2.6. Type B2
- 10.2.7. Type B3
- 10.3. Thymic carcinoma
- 10.4. Thymic Neuroendocrine Tumor (TNET)
- 10.5. Others
11. By Treatment
- 11.1. Introduction
- 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
- 11.1.2. Market Attractiveness Index, By Treatment
- 11.2. Surgery*
- 11.2.1. Introduction
- 11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 11.3. Chemotherapy
- 11.3.1. Doxorubicin (Adriamycin)
- 11.3.2. Cisplatin (Platinol)
- 11.3.3. Carboplatin (Paraplatin)
- 11.3.4. Others
- 11.4. Radiation therapy
- 11.5. Others
12. By End User
- 12.1. Introduction
- 12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 12.1.2. Market Attractiveness Index, By End User
- 12.2. Hospitals*
- 12.2.1. Introduction
- 12.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 12.3. Cancer Care and Research Centers
- 12.4. Ambulatory Surgery Centers
- 12.5. Academics and Research Institutes
13. By Region
- 13.1. Introduction
- 13.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 13.1.2. Market Attractiveness Index, By Region
- 13.2. North America
- 13.2.1. Introduction
- 13.2.2. Key Region-Specific Dynamics
- 13.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
- 13.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
- 13.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 13.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 13.2.6.1. The U.S.
- 13.2.6.2. Canada
- 13.2.6.3. Mexico
- 13.3. Europe
- 13.3.1. Introduction
- 13.3.2. Key Region-Specific Dynamics
- 13.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
- 13.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
- 13.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 13.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 13.3.6.1. Germany
- 13.3.6.2. The U.K.
- 13.3.6.3. France
- 13.3.6.4. Italy
- 13.3.6.5. Spain
- 13.3.6.6. Rest of Europe
- 13.4. South America
- 13.4.1. Introduction
- 13.4.2. Key Region-Specific Dynamics
- 13.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
- 13.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
- 13.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 13.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 13.4.6.1. Brazil
- 13.4.6.2. Argentina
- 13.4.6.3. Rest of South America
- 13.5. Asia-Pacific
- 13.5.1. Introduction
- 13.5.2. Key Region-Specific Dynamics
- 13.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
- 13.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
- 13.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 13.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 13.5.6.1. China
- 13.5.6.2. India
- 13.5.6.3. Japan
- 13.5.6.4. Australia
- 13.5.6.5. Rest of Asia-Pacific
- 13.6. Middle East and Africa
- 13.6.1. Introduction
- 13.6.2. Key Region-Specific Dynamics
- 13.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
- 13.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
- 13.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
14. Competitive Landscape
- 14.1. Competitive Scenario
- 14.2. Market Share Analysis
- 14.3. Mergers and Acquisitions Analysis
15. Company Profiles
- 15.1. Merck & Co., Inc.*
- 15.1.1. Company Overview
- 15.1.2. Product Portfolio and Description
- 15.1.3. Financial Overview
- 15.1.4. Key Developments
- 15.2. Viatris Inc.
- 15.3. F. Hoffmann-La Roche Ltd
- 15.4. Elekta AB
- 15.5. Asensus Surgical US, Inc.
- 15.6. Pfizer Inc.
- 15.7. Getwell Pharmaceuticals
- 15.8. Bristol-Myers Squibb Company
- 15.9. Intuitive Surgical
- 15.10. Varian Medical Systems, Inc. (Siemens Healthineers AG)
LIST NOT EXHAUSTIVE
16. Appendix
- 16.1. About Us and Services
- 16.2. Contact Us
